Bionano Genomics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Bionano reported Q3 2026 revenue of $8.3 million, up 12% compared with Q3 2025.
- The company sold 9,870 NanoChannel array flow cells, up 18% year over year and a record for any quarter.
- Consumable revenue was $4.7 million, up 24% year over year; software revenue was $1.1 million, down 31%; and other revenue, including instruments and services, was $2.5 million, up 24%.
- Revenue in Europe, the Middle East, and Africa grew 14% year over year to $4.1 million, while revenue in the Americas grew 35% to $3.8 million.
- Adjusted gross margin was 48%, compared with 46% in Q3 2025; operating expenses decreased 12% year over year to $10.5 million, and adjusted operating expenses decreased 9% to $8.8 million.
- Bionano ended the quarter with $8.7 million in cash, cash equivalents, and available-for-sale securities, including $500,000 subject to certain restrictions.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your first speaker today, Webb Campbell, Investor Relations.
Please go ahead. Thank you, Stephanie, and good afternoon, everyone.
Welcome to Bionano's third quarter 2026 financial results conference call. On the call with me today are Al Luderer, Chairman and Interim CEO of Bionano, and Mark Adamchak, Bionano's Chief Accounting Officer. After market closed today, Bionano issued a press release announcing its financial results for the third quarter 2026. A copy of the release can be found on the Investor Relations page of the company's website. Certain statements made during this conference call may be forward-looking statements. Actual results may differ materially from such statements due to several risk factors and risks, some of which are identified in Bionano's press release and Bionano's reports filed with the SEC. These forward-looking statements are based on information available to Bionano today, November 10, 2026, and the company assumes no obligation to update statements as circumstances change.
During our call, we may refer to certain non-GAAP financial measures, which we believe provide useful information for investors. Reconciliations of these measures to GAAP can be found in our press release and slide deck. An audio recording and webcast replay for today's conference call will also be available online on the Investor Relations page of the company website. With that, I will turn the call over to Al.
Thank you, Webb, and good afternoon, everyone. I am pleased to be here with you all today to share our third quarter 2026 results. Bionano delivered a strong third quarter. Our results reflect the trust our routine use customer base places on our products and the continued global utilization of optical genome mapping, or OGM, for discovering and analyzing diseases. Over the quarter, we saw momentum build across our business as well as the broader genomics community. Clinical adoption is what drives our results, and we saw progress on several fronts that make it easier for customers to bring OGM into routine practice. We expect that adoption, along with greater use at both existing and new clinical sites, to remain the foundation of our growth moving forward. We continue to pursue our mission of transforming pathology, the field devoted to understanding the causes, progression, and impact of disease.
Traditional methods for structural variant detection are costly, repetitive, labor-intensive, and time-consuming. By helping customers move to digital workflows supported by our consolidated platforms, automation, and decision intelligence software, we can provide a faster, more efficient, and more informative way to analyze the genome. Today, I will walk through how we have been advancing toward that goal across our four strategic pillars. I would like to take a moment to revisit the framework that guides how we execute. In September 2024, we made a deliberate shift away from aggressive installed base growth towards profitable growth with our existing routine use users. By placing an emphasis on prospects most likely to become routine, high-volume users, we have positioned ourselves to be a more focused, agile, and sustainable company. In practice, this is done through the following. First, to support and sustain our installed base of routine OGM and VIA software users.
Second, to increase OGM utilization by routine users by supporting menu expansion and improving ease of use with VIA and Ionic adoption. Third, to build the support needed for OGM reimbursement and inclusion in medical society guidelines and recommendations. Fourth, to improve profitability and scalability through lower costs, higher volumes, and continuous improvement in product quality. Turning to our first and second pillars, which are focused on supporting our installed base and driving greater utilization of our products, Q3 2026 flow cells sold were up 18% year-over-year at 9,870 units, a record for any quarter. In short, our customers are processing more samples than ever, and a large share of that added volume comes from laboratories bringing OGM into routine use.
Breaking down our revenue segments, consumable revenue was $4.7 million in Q3 2026, up 24% year-over-year, driven by sales to existing customers in the Americas. Software revenue was $1.1 million in Q3 2026, down 31% year-over-year, reflecting a lower number of VIA software licenses sold in the period. Other revenue, which includes instruments and services, was $2.5 million in Q3 2026, up 24% year-over-year, led by higher instrument sales to new customers. The continued move towards more recurring consumable-driven revenue gives us a healthier and more predictable business, and it is evidence of our strategy in action. I would also like to highlight the geographic profile of our quarter. Revenues in Europe, the Middle East, and Africa grew 14% year-over-year to $4.1 million, up from $3.6 million a year ago, driven by growth in instrument revenue.
Revenue in the Americas grew 35% year-over-year to $3.8 million. Adoption of OGM is not happening in a vacuum. Its value is being recognized globally as the investments we have made in evidence generation begin to translate to adoption. Regarding our second pillar, increasing OGM utilization by supporting software adoption and menu expansion, customers continue to give us very positive feedback on our software and compute upgrades that let them broaden their test menus and run more samples, and in some cases, have allowed them to double weekly cancer sample throughput with no change to their hardware. Our VIA software remains the gold standard for CNV analysis on microarrays, and we continue to see adoption among NGS and long-read sequencing labs. Customers who use VIA without OGM give us a base of software revenue, and this is often the first step towards using more of our platform.
Ionic, our system for producing high-purity DNA and RNA, also remains a key focus, supporting both OGM and NGS workflows at scale. We are increasingly seeing our software offerings as an on-ramp to broader OGM platform adoption. As we begin to see the transition of array VIA customers to OGM, we will eventually recognize some decline in software revenue, but expect to offset this loss by bringing these customers deeper into our OGM ecosystem. As we focus our resources on the largest opportunities in clinical OGM, we view the migration of these customers to OGM as a critical step forward for more routine use. Now, highlighting our third pillar, building support for OGM reimbursement and inclusion in medical society guidelines, an important development this quarter was MolDx's proposed local coverage determination, or LCD, for OGM.
In late August, MolDx published a proposed LCD that would set Medicare coverage in the Medicare administrative contractor jurisdictions that follow MolDx, representing 31 U.S. states. This coverage determination establishes a criteria for OGM-based genome-wide detection of copy number alterations and structural variants in hematologic neoplasms. The public comment period has now closed, and we look forward to the final determination. Today, Medicare is the largest payer for cancer care, and about 60% of new cancer diagnoses are in Medicare-eligible patients. MolDx states also represent roughly 61% of the U.S. population, and private insurers often write their policies in line with Medicare coverage. For laboratories, a clear coverage pathway lowers the financial risk of validating OGM and moving it into routine use, further supporting the broader adoption and utilization that drives demand for our products. This builds on the reimbursement foundation we described last quarter.
As we previously noted, the AMA has approved two category 1 CPT codes for OGM, one in hematologic malignancies and another for constitutional genetic disorders. Additionally, CMS has established reimbursement rates for both codes. The coverage determination from MolDx would add a clear path to Medicare coverage for OGM in hematologic malignancies. Together, we believe these developments are creating meaningful momentum for OGM and make it easier for customers to become routine users. Another milestone this quarter came in New York, where two leading academic centers are now bringing OGM into their clinical laboratories. The New York State Department of Health approved OGM-based laboratory-developed tests at University of Rochester Medicine, covering genetic disorders, reproductive disorders, and hematologic malignancies. Memorial Sloan Kettering Cancer Center then launched OGM-based hematologic malignancy testing following state approval. State approval is a significant step, allowing institutions to offer OGM testing in New York.
As more leading cancer centers adopt OGM in their clinical workflows, our base of routine users expands, subsequently driving utilization of our products. Now, expanding on our third pillar, the growing body of evidence continued this quarter with three new independent peer-reviewed publications showing the potential clinical value of OGM in high-risk myeloid cancers. The first, published in Modern Pathology by researchers at MD Anderson, used OGM to study 332 samples from subjects with myelodysplastic syndromes, or MDS. OGM identified chromoanagenesis, a catastrophic single-event genomic restructuring process, in 15.9% of cases overall and 17.6% of newly diagnosed subjects. These subjects had a median survival of 9.9 months, while the median survival for the rest of this group was much higher, as it had not been reached during the study. Researchers noted that this information could help doctors identify high-risk patients earlier and consider more aggressive treatments.
The second study, published in the International Journal of Cancer by the University of Oulu, Finland, analyzed 48 samples of cytogenetically normal acute myeloid leukemias. The study found that OGM detected clinically relevant structural variants in 46% of cases classified as normal by conventional karyotyping, and the presence of OGM-detected abnormalities was associated with worse survival in these individuals. The third study, published in npj Precision Oncology by the Josep Carreras Leukaemia Research Institute in Spain, studied subjects with therapy-related myeloid neoplasms and younger-onset MDS. It found that OGM produced a result in every sample, including all eight where conventional banding failed, and identified 134 additional genomic alterations. OGM-defined genomic groups showed significant differences in overall survival, with chromoanagenesis emerging as the strongest independent predictor of inferior overall survival.
These publications join the T-cell acute lymphoblastic leukemia study we highlighted last quarter, also published in Modern Pathology and conducted by researchers at MD Anderson and Johns Hopkins. Together, these publications, along with the 365 studies published year-to-date, give us confidence that the expanding body of clinical evidence is a leading indicator of future adoption and utilization of OGM. Turning to our fourth pillar, we continue to make progress on profitability. In 2023, our adjusted gross margin was in the low 20% range. Since then, we've steadily improved it, and in the third quarter, we generated a gross margin of 48% compared with 46% in the same quarter last year. We've applied the same discipline to our cost structure. Operating expenses decreased 12% year over year to $10.5 million, and adjusted operating expenses decreased 9% to $8.8 million.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
